BridgeBio Pharma, Inc. (BBIO) Financial Statements
$68.56NASDAQ: BBIOMarket Cap $13.40B
BridgeBio Pharma, Inc. most recently reported annual revenue of $502.0M, a net loss of $729.0M. Revenue grew at an average annual rate of 128.8% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
BridgeBio Pharma, Inc.: net profit was positive in 0 of 9 reported years; operating margin moved from -656.4% to -113.3%, a shift of +543.1 percentage points; the most recent year shows a net loss of $729.0M.
Income Statement — 9 Years (USD millions)
Metric
2017
2018
2019
2020
2021
2022
2023
2024
2025
Revenue
$0
$0
$41.0M
$8.0M
$70.0M
$78.0M
$9.0M
$222.0M
$502.0M
Operating Expenses
$44.0M
$184.0M
$307.0M
$483.0M
$646.0M
$590.0M
$617.0M
$815.0M
$1.1B
Operating Profit
$-44.0M
$-184.0M
$-266.0M
$-474.0M
$-577.0M
$-512.0M
$-607.0M
$-593.0M
$-569.0M
Operating Margin
0.0%
0.0%
-656.4%
-5752.0%
-827.1%
-659.6%
-6528.8%
-267.2%
-113.3%
Other Income
$0
$14.0M
$-22.0M
$-31.0M
$-10.0M
$28.0M
$-46.0M
$51.0M
$-166.0M
Interest
$0
$3.0M
$9.0M
$37.0M
$47.0M
$80.0M
$81.0M
$99.0M
$53.0M
Depreciation
$0
$0
$1.0M
$1.0M
$6.0M
$7.0M
$6.0M
$6.0M
$5.0M
Profit Before Tax
$-44.0M
$-169.0M
$-289.0M
$-505.0M
$-586.0M
$-485.0M
$-653.0M
$-542.0M
$-735.0M
Tax
$0
$0
$0
$0
$0
$0
$0
$-210,000
$-80,000
Net Profit
$-31.0M
$-131.0M
$-260.0M
$-449.0M
$-563.0M
$-481.0M
$-643.0M
$-536.0M
$-729.0M
EPS
$-0.33
$-1.42
$-2.48
$-4.10
$-3.90
$-3.35
$-3.95
$-2.88
$-3.79
Dividend Payout
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Results — Last 12 Quarters (USD millions)
8 duplicate period labels in the source data were collapsed.
Metric
Sep '23
Dec '23
Mar '24
Jun '24
Sep '24
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Revenue
$4.0M
$2.0M
$211.0M
$2.0M
$3.0M
$6.0M
$117.0M
$111.0M
$121.0M
$154.0M
$195.0M
$222.0M
Operating Expenses
$162.0M
$179.0M
$211.0M
$178.0M
$194.0M
$232.0M
$221.0M
$245.0M
$266.0M
$339.0M
$300.0M
$330.0M
Operating Profit
$-158.0M
$-177.0M
$0
$-176.0M
$-192.0M
$-226.0M
$-104.0M
$-134.0M
$-145.0M
$-185.0M
$-106.0M
$-107.0M
Operating Margin
-3854.6%
-10167.1%
0.2%
-8096.8%
-7018.7%
-3842.7%
-89.5%
-121.5%
-120.3%
-120.1%
-54.5%
-48.1%
Interest
$20.0M
$20.0M
$23.0M
$23.0M
$23.0M
$30.0M
$42.0M
$38.0M
$12.0M
$12.0M
$53.0M
$13.0M
Profit Before Tax
$-179.0M
$-170.0M
$-36.0M
$-76.0M
$-164.0M
$-266.0M
$-170.0M
$-182.0M
$-186.0M
$-197.0M
$-167.0M
$-156.0M
Tax
$0
$0
$0
$0
$0
$-430,000
$0
$-1.2M
$830,000
$0
$0
$0
Net Profit
$-177.0M
$-168.0M
$-35.0M
$-73.0M
$-162.0M
$-265.0M
$-167.0M
$-182.0M
$-183.0M
$-197.0M
$-164.0M
$-152.0M
EPS
$-1.08
$-0.96
$-0.20
$-0.39
$-0.86
$-1.40
$-0.88
$-0.95
$-0.96
$-1.00
$-0.84
$-0.78
Over the 9 years reported for BridgeBio Pharma, Inc., borrowings increased from $144.0M in 2017 to $2.7B in 2025, cash stood at $570.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 2.62 times.
Balance Sheet — 9 Years (USD millions)
Metric
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
$98.0M
$465.0M
$632.0M
$704.0M
$1.0B
$623.0M
$546.0M
$919.0M
$936.0M
Current Assets
$97.0M
$445.0M
$569.0M
$643.0M
$889.0M
$549.0M
$478.0M
$721.0M
$754.0M
Cash
$92.0M
$436.0M
$364.0M
$356.0M
$394.0M
$377.0M
$376.0M
$681.0M
$570.0M
Inventory
$0
$0
$0
$0
$0
$0
$0
$0
$27.0M
Receivables
$0
$0
$3.0M
$0
$20.0M
$17.0M
$2.0M
$5.0M
$139.0M
Fixed Assets
$0
$2.0M
$6.0M
$37.0M
$46.0M
$25.0M
$20.0M
$13.0M
$14.0M
Capital Work in Progress
$0
$0
$0
$0
$0
$0
$0
$0
$0
Investments
$0
$17.0M
$213.0M
$251.0M
$445.0M
$98.0M
$63.0M
$144.0M
$99.0M
Other Assets
$0
$0
$0
$0
$0
$0
$0
$0
$0
Total Liabilities
$153.0M
$566.0M
$156.0M
$596.0M
$1.9B
$1.9B
$1.9B
$2.4B
$3.0B
Current Liabilities
$9.0M
$33.0M
$60.0M
$96.0M
$135.0M
$121.0M
$144.0M
$154.0M
$288.0M
Borrowings
$144.0M
$55.0M
$92.0M
$496.0M
$1.7B
$1.7B
$1.7B
$1.7B
$2.7B
Other Liabilities
$9.0M
$512.0M
$64.0M
$100.0M
$152.0M
$144.0M
$149.0M
$646.0M
$284.0M
Equity
$3.0M
$7.0M
$0
$0
$0
$0
$0
$0
$0
Reserves
$-58.0M
$-164.0M
$408.0M
$58.0M
$-870.0M
$-1.3B
$-1.4B
$-1.5B
$-2.1B
For BridgeBio Pharma, Inc., operating cash flow was positive in 0 of 9 reported years; free cash flow in the latest year was negative at $447.0M; free cash flow was positive in 0 of 9 years; financing activities used $60.0M in the latest year, which covers debt repayment, dividends and buybacks.
Cash Flow Statement — 9 Years (USD millions)
Metric
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating Cash Flow
$-40.0M
$-137.0M
$-254.0M
$-400.0M
$-498.0M
$-419.0M
$-528.0M
$-521.0M
$-446.0M
Investing Cash Flow
$2.0M
$-42.0M
$-222.0M
$-61.0M
$-249.0M
$447.0M
$53.0M
$60.0M
$-26.0M
Financing Cash Flow
$2.0M
$15.0M
$-4.0M
$-103.0M
$-343.0M
$3.0M
$2.0M
$-43.0M
$-60.0M
Net Cash Flow
$72.0M
$344.0M
$-72.0M
$-6.0M
$38.0M
$21.0M
$-22.0M
$289.0M
$-111.0M
Free Cash Flow
$-41.0M
$-155.0M
$-259.0M
$-407.0M
$-546.0M
$-426.0M
$-529.0M
$-522.0M
$-447.0M
Valuation & Return Ratios
Metric
Value
PEG Ratio
-1.47
EV / EBITDA
-24.64
FCF Yield
-3.32%
Quick Ratio
1.17
Interest Coverage
-6.05
Return 1Y
18.49%
Return 3Y
152.11%
Return 5Y
35.43%
BridgeBio Pharma, Inc. (BBIO) financials — frequently asked questions
What is BridgeBio Pharma, Inc.'s annual revenue?
BridgeBio Pharma, Inc. (BBIO) reported annual revenue of $502.0M in its most recent fiscal year.
What is BridgeBio Pharma, Inc.'s net profit?
BridgeBio Pharma, Inc. (BBIO) reported a net loss of $729.0M in its most recent fiscal year.
What is BBIO EV/EBITDA?
BridgeBio Pharma, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -24.64. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.